{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:08:49Z","timestamp":1793898529744,"version":"4.8.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Systemic mastocytosis (SM) is a rare hematologic condition characterized by the proliferation and accumulation in tissue of clonal mast cells in multiple organ systems. The release of mast cell mediators in the indolent disease type and the predominant mast cell infiltration of tissues in advanced disease contribute to the heterogeneous clinical presentation. The disease driver in &amp;gt;90% of adult cases is an activating <jats:italic>KIT<\/jats:italic> mutation, with D816V being the most frequent. Here we describe a case of a young adult male presenting with osteoporosis with associated symptoms of reflux and a history of bee sting anaphylaxis. A multidisciplinary approach to the diagnosis and management was required to minimize morbidities and prevent complications. Current best supportive care was inadequate to control the patient's disease, and a selective KIT D816V inhibitor (avapritinib) was initiated. Conventional, and advanced therapies, including those in the treatment pipeline for SM are discussed.<\/jats:p>","DOI":"10.3389\/falgy.2024.1401187","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:10:15Z","timestamp":1729228215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms"],"prefix":"10.3389","volume":"5","author":[{"given":"Matthew J.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren W.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Arana Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana C.","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-1961","DOI":"10.12688\/f1000research.19463.1","article-title":"Recent advances in the understanding and therapeutic management of mastocytosis","volume":"8","author":"Rossignol","year":"2019","journal-title":"F1000Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rmed.2011.09.007","article-title":"The role of mast cells in allergic inflammation","volume":"106","author":"Amin","year":"2012","journal-title":"Respir Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/CPAA.S206615","article-title":"Novel approaches to treating advanced systemic mastocytosis","volume":"11","author":"Gilreath","year":"2019","journal-title":"Clin Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/joim.12410","article-title":"Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease","volume":"279","author":"Gulen","year":"2016","journal-title":"J Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.dld.2006.06.003","article-title":"Aggressive systemic mastocytosis complicated by protein-losing enteropathy","volume":"39","author":"Mickys","year":"2007","journal-title":"Dig Liver Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.jaip.2022.03.001","article-title":"Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US Cooperative Group","volume":"10","author":"Hoermann","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.iac.2014.01.005","article-title":"Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells","volume":"34","author":"Horny","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-pathol-052016-100312","article-title":"Pathogenesis and pathology of mastocytosis","volume":"12","author":"Metcalfe","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.gastro.2017.12.029","article-title":"A case of cryptogenic liver failure","volume":"155","author":"Jiang","year":"2018","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/modpathol.2008.158","article-title":"Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases","volume":"21","author":"Kirsch","year":"2008","journal-title":"Mod Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1365-2796.1993.tb00984.x","article-title":"Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis","volume":"233","author":"Kors","year":"1993","journal-title":"J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.7860\/JCDR\/2013\/5669.3493","article-title":"Systemic mastocytosis: predominantly involving the bone, a case report","volume":"7","author":"Mallya","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"B19","article-title":"Rare Disease Database: Mastocytosis","year":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1016\/j.jaip.2020.05.005","article-title":"Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis","volume":"8","author":"Schwaab","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1046\/j.1365-2044.1998.00536.x","article-title":"Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia","volume":"53","author":"Vaughan","year":"1998","journal-title":"Anaesthesia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S0140-6736(13)61605-0","article-title":"Anaphylaxis caused by mosquito allergy in systemic mastocytosis","volume":"382","author":"Reiter","year":"2013","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1127.e1","DOI":"10.1016\/j.amjmed.2014.06.015","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","journal-title":"Am J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","article-title":"The international consensus classification of mastocytosis and related entities","volume":"482","author":"Leguit","year":"2023","journal-title":"Virchows Arch"},{"key":"B28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","article-title":"Endocrine manifestations of systemic mastocytosis in bone","volume":"17","author":"Greene","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"B29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am J Med"},{"key":"B31","first-page":"239","article-title":"A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk: romosozumab (evenity(R)), a humanized monoclonal anti-sclerostin antibody","volume":"78","author":"Bolland","year":"2023","journal-title":"Rev Med Liege"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.3390\/cancers13133316","article-title":"Gastrointestinal manifestations in systemic mastocytosis: the need of a multidisciplinary approach","volume":"13","author":"Zanelli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/PAS.0b013e318078ce7a","article-title":"Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis","volume":"31","author":"Hahn","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B37","first-page":"186","article-title":"The efficacy of oral disodium cromoglycate in human mastocytosis","volume":"63","author":"Wasserman","year":"1979","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/imt.11.44","article-title":"Venom immunotherapy in patients with mastocytosis and Hymenoptera venom anaphylaxis","volume":"3","author":"Gonzalez-de-Olano","year":"2011","journal-title":"Immunotherapy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaci.2007.11.010","article-title":"Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis","volume":"121","author":"Gonzalez-de-Olano","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jaip.2019.10.022","article-title":"One-day ultrarush desensitization for Hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant omalizumab","volume":"8","author":"Giannetti","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11882-015-0582-5","article-title":"Hymenoptera allergy and mast cell activation syndromes","volume":"16","author":"Bonadonna","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","article-title":"A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis","volume":"147","author":"Carter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/all.15911","article-title":"Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals","volume":"79","author":"Gonzalez-de-Olano","year":"2024","journal-title":"Allergy"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jid.2020.12.030","article-title":"Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis","volume":"141","author":"Aberer","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdcr.2016.11.004","article-title":"Intertriginous maculopapular mastocytosis in a patient with acute myeloid leukemia","volume":"3","author":"Herrero-Moyano","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/ijd.14166","article-title":"Intertriginous mastocytosis: a rare presentation of an uncommon disease","volume":"58","author":"Simmons","year":"2019","journal-title":"Int J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/bjd.17897","article-title":"Image gallery: the vulva: an atypical localization of mastocytosis in adulthood","volume":"181","author":"Bulai Livideanu","year":"2019","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.1111\/ijd.14385","article-title":"Palmoplantar maculopapular cutaneous mastocytosis","volume":"58","author":"Sammut","year":"2019","journal-title":"Int J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2230.2008.02931.x","article-title":"Cutaneous mastocytosis localized to a radiotherapy field","volume":"34","author":"Soilleux","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-2133.1975.tb06482.x","article-title":"Pseudoxanthomatous mastocytosis","volume":"93","author":"Griffiths","year":"1975","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4103\/0019-5154.185751","article-title":"Adult onset of xanthelasmoid mastocytosis: report of a rare entity","volume":"61","author":"Nabavi","year":"2016","journal-title":"Indian J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/modpathol.2013.117","article-title":"Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis","volume":"27","author":"Berezowska","year":"2014","journal-title":"Mod Pathol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20098","article-title":"Cutaneous mastocytosis in adults with a serum tryptase level <20\u2005ng ml(-1): why we should investigate further","volume":"185","author":"Jendoubi","year":"2021","journal-title":"Br J Dermatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ajcp\/aqaa183","article-title":"Mastocytosis","volume":"155","author":"Tzankov","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/phpp.12248","article-title":"Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients","volume":"32","author":"Brazzelli","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B58","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2340\/00015555-1788","article-title":"Increased risk of malignant melanoma in patients with systemic mastocytosis?","volume":"94","author":"Hagglund","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9840","DOI":"10.3390\/ijms24129840","article-title":"Mastocytosis and skin cancer: the current state of knowledge","volume":"24","author":"Kaszuba","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am J Hematol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/s41591-021-01588-z","article-title":"Finding the right KIT inhibitor for advanced systemic mastocytosis","volume":"27","author":"Castells","year":"2021","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"B64","article-title":"FDA Approves AYVAKIT\u00ae (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis [press release]","year":""},{"key":"B65","volume-title":"AYVAKIT\u00ae [prescribing information]","year":"2023"},{"key":"B66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-136632","article-title":"Pioneer part 2: a randomized, double-blind, placebo-controlled, phase 2 study to evaluate safety and efficacy of avapritinib in indolent systemic mastocytosis","volume":"136","author":"Akin","year":"2020","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evidence"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1401187\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:10:18Z","timestamp":1729228218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1401187\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":68,"alternative-id":["10.3389\/falgy.2024.1401187"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1401187","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"article-number":"1401187"}}